GLobal Biopharmaceutical Company Hires Leading PR Firm as it...

GLobal Biopharmaceutical Company Hires Leading PR Firm as it Expands Their U.S.Operations NEW YORK, April 19, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals ("Paradigm"), aglobal biopharmaceutical company specializing in repurposing existing drugs for unmetmedical needs, announced their retention of Rubenstein Public Relations (RPR) as itsagency of record. Paradigm recently announced the expansion of their U.S. operations to support a phaseIII registration study for Zilosul(R) (pentosan polysulfate sodium, PPS), a new potentialtherapy for osteoarthritis of the knee (kOA). Osteoarthritis is a common cause ofdisability among adults and affects more than 72 million people across the U.S., Canada,EU-5, and Australia. RPR will provide counsel to Paradigm on their corporate messaging and guide thedevelopment of their brand positioning in both the U.S. and global markets. "We are excited to begin our partnership with RPR, as their firm is well-equipped toguide our company across the U.S. media landscape and highlight our innovative therapieswhich have the potential to enhance the quality of life of millions," said Paradigm CMOand Interim CEO, Dr. Donna Skerrett. RPR President, Richard Rubenstein said, "Paradigm has tremendous growth potential inthe U.S. market, as their drug for osteoarthritis Zilosul(R) may address a large unmetmedical need for effective OA therapies. Furthermore, Zilosul(R) has demonstratedencouraging data for the treatment of OA pain and the drug's potential for diseasemodification." "Paradigm has had a successful kickoff for their global phase III trial in the U.S. andAustralia, with sites in the UK, Europe and Canada opening soon," he added. In addition to osteoarthritis, Paradigm is also in phase II studies investigating thepotential for PPS as adjunct therapy to manage musculoskeletal symptoms associated withthe rare disease mucopolysaccharidosis. Utilizing their long-standing expertise and experience in the biotech and pharmaindustries, RPR will also help direct the expansion of Paradigm's U.S. operations. For more information on Paradigm, visit https://paradigmbiopharma.com/. About Rubenstein Public Relations: Rubenstein Public Relations (RPR) is an independent, New York-based communicationsagency headed by veteran publicist and respected brand architect, Richard Rubenstein. Formore than three decades, RPR's intensive media relations approach and dedicated team ofsenior practitioners have helped clients build brand equity and reach their targetaudiences. The firm specializes in brand messaging development, media relations, crisiscommunications, and thought leadership positioning. RPR has a proven track record inexecuting successful public relations campaigns for leading corporate, real estate,technology, healthcare, social impact, luxury consumer, entertainment, and hospitalitybrands across the globe. http://www.rubensteinpr.com